Vaginal AtrophyPhase 3NCT01358760

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

A Phase 3 study testing DHEA in people with Vaginal Atrophy, run by EndoCeutics Inc. at 42 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy. Read more about this study

Who is it for?: Ages 40 to 75 years, women only
Conditions the study is for: Vaginal Atrophy
What is being tested?: DHEA
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 450 participants
Where: 42 sitesin 2 countries
Study dates: Jun 2011to May 2012
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 to 75 years
Women only
No healthy volunteers
Adult, Older adult

Who may be able to join

Postmenopausal women (non-hysterectomized or hysterectomized)
Women between 40 and 75 years of age
Willing to participate in the study and sign an informed consent
Women who have self-identified symptom(s) of vaginal atrophy
For non-hysterectomized women, willing to have endometrial biopsy at baseline and end of study

Who cannot join

Undiagnosed abnormal genital bleeding
Hypertension equal to or above 140/90 mm Hg
The administration of any investigational drug within 30 days of screening visit
Endometrial hyperplasia, cancer or endometrial histology showing proliferative, secretory or menstrual type characteristics at histologic evaluation of endometrial biopsy performed at screening

Trial locations and contacts

42 sites in 2 countries.

Country

City, postcode or hospital

42 sites in 2 countries

United States32 sites

EndoCeutics site # 27
Baltimore, Maryland, 21285-6815
EndoCeutics site # 33
Beachwood, Ohio, 44122
EndoCeutics site # 05
Cleveland, Ohio, 44122
EndoCeutics site # 47
Cleveland, Ohio, 44124
EndoCeutics site # 15
Columbus, Ohio, 43213
EndoCeutics site # 66
Danbury, Connecticut, 06810
EndoCeutics site # 36
Denver, Colorado, 80218
EndoCeutics site # 52
Denver, Colorado, 80220
EndoCeutics site # 64
Jackson, Tennessee, 38305
EndoCeutics site # 26
Jacksonville, Florida, 32207
EndoCeutics site # 60
Lake Worth, Florida, 33461
EndoCeutics site # 65
Little Rock, Arkansas, 72204
EndoCeutics site # 63
Memphis, Tennessee, 38120
EndoCeutics site # 10
Meridian, Idaho, 83642
EndoCeutics site # 42
Milford, Connecticut, 06460
EndoCeutics site # 39
Montgomery, Alabama, 36117
EndoCeutics site # 50
Neptune City, New Jersey, 07753
EndoCeutics site # 61
Newark, Delaware, 19718
EndoCeutics site # 03
Norfolk, Virginia, 23507
EndoCeutics site # 54
North Miami, Florida, 33161
EndoCeutics site # 24
Omaha, Nebraska, 68131
EndoCeutics site # 56
Pinellas Park, Florida, 33781
EndoCeutics site # 62
Providence, Rhode Island, 02930
EndoCeutics site # 21
Sacramento, California, 95821
EndoCeutics site # 53
San Antonio, Texas, 78205
EndoCeutics site # 30
San Diego, California, 92108
EndoCeutics site # 51
Sandy City, Utah, 84070
EndoCeutics site # 23
Sandy Springs, Georgia, 30328
EndoCeutics site # 14
Tucson, Arizona, 85712
EndoCeutics site # 57
West Hartford, Connecticut, 06117
EndoCeutics site # 09
West Jordan, Utah, 84088
EndoCeutics site # 55
Wichita, Kansas, 67226

Other trials in United States

Canada10 sites

EndoCeutics site # 06
Bathurst, New Brunswick, E2A 4X7
EndoCeutics site # 13
Calgary, Alberta, T2N 4L7
EndoCeutics site # 04
Drummondville, Quebec, J2B 7T1
EndoCeutics site # 12
Montreal, Quebec, H4N 3C5
EndoCeutics site # 02
Québec, Quebec, G1S 2L6
EndoCeutics site # 01
Québec, Quebec, G1V 2L9
EndoCeutics site # 18
Saint Romuald, Quebec, G6W 5M6
EndoCeutics site # 08
Shawinigan, Quebec, G9N 2H6
EndoCeutics site # 11
Sherbrooke, Quebec, J1H 1Z1
EndoCeutics site # 59
Toronto, Ontario, M5B 1W8

Other trials in Canada

About this study

The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.

Conditions: Vaginal Atrophy
Being tested: Placebo, DHEA
Keywords: Vulvar/vaginal atrophy, Atrophic Vaginitis, Dehydroepiandrosterone, DHEA, Prasterone, Vaginorm, Menopause, Intrarosa
Medical subject headings: Atrophic Vaginitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

PlaceboDrug
Placebo vaginal suppository
DHEADrug
Also called Prasterone, Dehydroepiandrosterone
Vaginal suppository containing 0.25% (3.25 mg) DHEA
DHEADrug
Also called Prasterone, Dehydroepiandrosterone
Vaginal suppository containing 0.5% (6.5 mg) DHEA

Study groups in NCT01358760
Study group	Role	What they receive
Placebo	Placebo comparator	Not described Receives: Drug: Placebo
0.25% DHEA	Experimental	Not described Receives: Drug: DHEA
0.5% DHEA	Experimental	Not described Receives: Drug: DHEA

What is being measured

The primary outcome is the main question the study is designed to answer.

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear
The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Measured: Baseline and Week 12
Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear
The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Measured: Baseline and Week 12
Change From Baseline to Week 12 in Vaginal pH
A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Measured: Baseline and Week 12
Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness
The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Measured: Baseline and Week 12

Secondary outcomes (5)

Change From Baseline to Week 12 in Severity of Dyspareunia
The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Measured: Baseline and Week 12
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Measured: Baseline and Week 12
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Measured: Baseline and Week 12
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Measured: Baseline and Week 12
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Measured: Baseline and Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Jun 2011May 2012

First posted24 May 2011 (estimated)
Study startJun 2011
Primary completionApr 2012
Study completionMay 2012

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (2)Papers the sponsor has linked to this study.
Other trials for Vaginal AtrophyStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 450 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01358760
Sponsor's protocol ID: ERC-234
Status last verified: Jun 2017
First submitted: 20 May 2011
Last updated: 12 Jun 2017
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes

Publications

Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi E, Grainger DA, Ayotte N, Cooper TA, Martens M, Waldbaum AS, Labrie C, Cote I, Lavoie L, Martel C, Balser J; VVA Prasterone Group. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric. 2015;18(4):590-607. doi: 10.3109/13697137.2014.992012. Epub 2015 Mar 3.
PubMed 25511551
Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dube R; other participating members of VVA Prasterone Group. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015 Dec;22(12):1289-95. doi: 10.1097/GME.0000000000000470.
PubMed 25968836

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 3
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
Vaginal Atrophy, Breast Carcinoma
RecruitingPhase 2
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Vulvo Vaginal Atrophy (VVA)
Recruiting
F-GYN for Vaginal Dryness and Vulvovaginal Atrophy
Atrophic Vaginitis, Atrophic Vulvovaginitis
Recruiting
A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.
Female Urogenital Diseases, Breast Cancer Female
Not yet recruitingObservational study
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
Vulvar Atrophy, Vulvovaginal Signs and Symptoms

All Vaginal Atrophy trials

Study at a glance

From the registry record, last updated by the sponsor on 12 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
ClinicalTrials.gov ID: NCT01358760
Acronym / sponsor ID: ERC-234
Conditions: Vaginal Atrophy
Keywords: Vulvar/vaginal atrophy, Atrophic Vaginitis, Dehydroepiandrosterone, DHEA, Prasterone, Vaginorm, Menopause, Intrarosa
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 450 participants (actual)
Lead sponsor: EndoCeutics Inc.Industry (pharma, biotech, devices)
Study start: Jun 2011
Primary completion: Apr 2012 (actual)
Study completion: May 2012 (actual)
First posted: 24 May 2011 (estimated)
Results: Posted 12 Jun 2017

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 3

Arm	Type	Receives
Placebo	Placebo comparator	Drug: Placebo
0.25% DHEA	Experimental	Drug: DHEA
0.5% DHEA	Experimental	Drug: DHEA

Who may qualify

Ages: 40 to 75 years
Sex: Female only
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Postmenopausal women (non-hysterectomized or hysterectomized)
Women between 40 and 75 years of age
Willing to participate in the study and sign an informed consent
Women who have self-identified symptom(s) of vaginal atrophy
For non-hysterectomized women, willing to have endometrial biopsy at baseline and end of study

Key exclusion criteria (4 listed)

Undiagnosed abnormal genital bleeding
Hypertension equal to or above 140/90 mm Hg
The administration of any investigational drug within 30 days of screening visit
Endometrial hyperplasia, cancer or endometrial histology showing proliferative, secretory or menstrual type characteristics at histologic evaluation of endometrial biopsy performed at screening

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
PlaceboPlacebo vaginal suppository	Drug	Placebo
DHEAAlso: Prasterone, DehydroepiandrosteroneVaginal suppository containing 0.25% (3.25 mg) DHEA	Drug	0.25% DHEA
DHEAAlso: Prasterone, DehydroepiandrosteroneVaginal suppository containing 0.5% (6.5 mg) DHEA	Drug	0.5% DHEA

Primary outcome

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear
Time frame: Baseline and Week 12
The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear
Time frame: Baseline and Week 12
The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Vaginal pH
Time frame: Baseline and Week 12
A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness
Time frame: Baseline and Week 12
The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.

5 secondary outcomes

Change From Baseline to Week 12 in Severity of Dyspareunia
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color
Time frame: Baseline and Week 12

Results and safety

Results posted to the registry on 12 Jun 2017, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Placebo	152	130
0.25% DHEA	148	128
0.50% DHEA	150	125

Primary outcome: Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Time frame: Baseline and Week 12. Mean (Standard Error). Unit: percentage of parabasal cells

Measure	Placebo n = 139	0.25% DHEA n = 134	0.50% DHEA n = 134
Baseline	60.66 (3.40)	56.74 (3.69)	59.54 (3.41)
Week 12	62.22 (3.49)	39.23 (3.15)	33.02 (3.09)
Change from Baseline to Week 12	1.56 (1.98)	-17.51 (2.74)	-26.52 (2.94)

Population analysed: Efficacy analyses were performed primarily on the Intent to Treat (ITT) population defined as all subjects who have received at least one dose of study drug with a baseline (Day 1) evaluation meeting the study entry criteria.

Primary outcome: Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Time frame: Baseline and Week 12. Mean (Standard Error). Unit: percentage of superficial cells

Measure	Placebo n = 139	0.25% DHEA n = 134	0.50% DHEA n = 134
Baseline	0.97 (0.13)	1.12 (0.13)	0.93 (0.11)
Week 12	1.80 (0.29)	3.43 (0.34)	3.58 (0.41)
Change from Baseline to Week 12	0.83 (0.26)	2.31 (0.32)	2.66 (0.41)

Primary outcome: Change From Baseline to Week 12 in Vaginal pH

Time frame: Baseline and Week 12. Mean (Standard Error). Unit: pH units

Measure	Placebo n = 139	0.25% DHEA n = 134	0.50% DHEA n = 134
Baseline	6.34 (0.05)	6.27 (0.06)	6.29 (0.06)
Week 12	6.06 (0.08)	5.69 (0.09)	5.67 (0.08)
Change from Baseline to Week 12	-0.28 (0.06)	-0.58 (0.07)	-0.62 (0.07)

Primary outcome: Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness

Time frame: Baseline and Week 12. Mean (Standard Error). Unit: Severity score

Measure	Placebo n = 139	0.25% DHEA n = 134	0.50% DHEA n = 134
Baseline	2.38 (0.04)	2.37 (0.04)	2.35 (0.04)
Week 12	1.27 (0.07)	1.10 (0.07)	1.13 (0.08)
Change from Baseline to Week 12	-1.12 (0.08)	-1.28 (0.08)	-1.22 (0.08)

5 secondary outcomes are reported in the full results.

Adverse events

Time frame: From Baseline to Week 12 (+ 30-day follow-up period after last dose). Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Placebo	5 of 150 (3.3%)	19 of 150 (12.7%)	Not reported
0.25% DHEA	1 of 143 (0.7%)	17 of 143 (11.9%)	Not reported
0.50% DHEA	1 of 148 (0.7%)	23 of 148 (15.5%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2017.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Results publication: PubMed 25511551Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi E, Grainger DA, Ayotte N, Cooper TA, Martens M, Waldbaum AS, Labrie C, Cote I, Lavoie L, Martel C, Balser J; VVA Prasterone Group. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric. 2015;18(4):590-607. doi: 10.3109/13697137.2014.992012. Epub 2015 Mar 3.
Results publication: PubMed 25968836Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dube R; other participating members of VVA Prasterone Group. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015 Dec;22(12):1289-95. doi: 10.1097/GME.0000000000000470.

Related trials for Vaginal Atrophy

RecruitingPhase 3
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
Vaginal Atrophy, Breast Carcinoma
RecruitingPhase 2
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Vulvo Vaginal Atrophy (VVA)
Recruiting
F-GYN for Vaginal Dryness and Vulvovaginal Atrophy
Atrophic Vaginitis, Atrophic Vulvovaginitis
Recruiting
A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.
Female Urogenital Diseases, Breast Cancer Female
Not yet recruitingObservational study
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
Vulvar Atrophy, Vulvovaginal Signs and Symptoms

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

David Archer, MD principal investigator

Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA

42 sites in 2 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing DHEA in people with Vaginal Atrophy, run by EndoCeutics Inc. at 42 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 42 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 12 Jun 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear (time frame: Baseline and Week 12). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01358760, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2017.